Lenalidomide: all 818 studies that test it
Page 9 of 9. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple MyelomaCompletedNCT00151203Phase 2
- Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar RadiculopathyCompletedNCT00120120Phase 2/3
- Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic SyndromesCompletedNCT00104962Phase 1
- Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
- Lenalidomide in Treating Patients With Advanced or Unresectable Kidney CancerCompletedNCT00096525Phase 2
- Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy IICompletedNCT00093028Phase 3
- A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)CompletedNCT00091624Phase 1
- A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)CompletedNCT00067743Phase 2
- Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT00065351Phase 2
- Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic SyndromesCompletedNCT00064974Phase 2
- Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.CompletedNCT00057616Phase 3
- Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaCompletedNCT00055562Phase 2/3
- A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple MyelomaCompletedNCT00051116Phase 2
- Phase 1 Study OF CDC-501 in Patients With Solid TumorsCompletedNCT00046735Phase 1
- Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic SyndromeCompletedNCT00044382Phase 2
- CDC-501 Therapy in Relapsed or Refractory Multiple MyelomaCompletedNCT00044018Phase 2
- CC-5013 in Treating Patients With Recurrent GliomaCompletedNCT00036894Phase 1
- CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous TherapyCompletedNCT00031941Phase 1